联化科技: 关于股票交易异常波动的公告

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days (May 27, 28, and 29, 2025) [1] - The company operates under a CDMO business model, providing advanced intermediates of chlorantraniliprole to a long-term partner, with no notification of increased demand from this customer [1] - The company has not identified any significant undisclosed information in public media that could have impacted its stock price [1] Group 2 - The board confirmed that there are no undisclosed matters that should be reported according to the Shenzhen Stock Exchange listing rules, nor any related negotiations or agreements [2] - The company has not found any need to correct or supplement previously disclosed information [2]